Bionano reports second quarter 2024 results and highlights recent business progress

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from q2 2023 total installed base of 363 optical genome mapping (ogm) systems as of q2 2024, which represents a 29% increase over q2 2023 sold 6,165 nanochannel array flowcells in q2 2024, which represents a 13% decrease from the number of flowcells sold in q2 2023 the editorial panel of the american medical association (ama) established a new category i current procedural terminology (cpt®) code for the use of ogm in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies conference call today, august 7th, 2024 at 4:30 pm et san diego, aug. 07, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today reported financial results for the second quarter ended june 30, 2024. “we saw positive growth in the ogm installed base this quarter, along with key advancements to our via software and the achievement of a significant milestone with the establishment of a category i cpt code for ogm, which we believe will raise the awareness and utility of ogm,” commented erik holmlin, phd, president and chief executive officer of bionano.
BNGO Ratings Summary
BNGO Quant Ranking